NCT01962051撤回不适用
AMPLATZER Cardiac Plug (ACP) Latin American Post Market Observational
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 主要终点
- Evaluate the performance of the ACP device in closure of the LAA
研究概览
简要总结
The ACP device will be clinically evaluated through a prospective, open-label, nonrandomized, multi-center post market clinical study.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must have a documented history of paroxysmal, persistent or permanent nonvalvular atrial fibrillation (documentation may include an electrocardiogram (ECG), Holter, or event recorder)
- •Subject must have a LAA closure procedure that has already been planned or scheduled by his/her attending physician before entry in the study
- •Subject must be greater than or equal to 18 years of age
排除标准
- •Subject with an implanted atrial septal defect (ASD) device or patent foramen ovale (PFO) device
- •Subject underwent LAA closure procedure prior to study entry (i.e. before signing informed consent
- •Subject who has a history of surgical ASD or PFO repair
- •Subject with a history of stroke and unrepaired PFO
- •Subject who has moderate to severe aortic or mitral valve stenosis or regurgitation requiring surgical or percutaneous intervention as assessed by the Investigator
- •Subject who has a mitral or aortic prosthetic valve
- •Subject with NYHA grade 4
- •Subject with evidence of moderate pericardial effusion at baseline evaluation
- •Subject who has complex atheroma with mobile plaque of the descending aorta and/or aortic arch
- •Subject who has an intracardiac thrombus
- •Subject who has carotid disease as assessed by the Investigator, requiring treatment, which includes revascularization and/or medical treatment
- •Subject with active infection or active endocarditis
- •Subject who has an acute or recent myocardial infarction (MI) or unstable angina (recent is defined as within 3 months of implant date)
- •Subject who has had recent major cardiac surgical procedure (recent is defined as within 6 months of implant date)
- •Subject with malignancy or other illness where life expectancy is less than one year
- •Subject who is pregnant, breastfeeding, or desires to become pregnant during their first six months of follow-up
- •Subject or legally authorized representative who is unable to provide informed consent
- •Subject who will not be able to be followed for the duration of the clinical study
- •Subject with any medical disorder or severe disability that would interfere with completion or evaluation of clinical study results (for example uncontrolled hypertension, uncontrolled diabetes, blood disorder, renal failure, in situ IVC filter)
结局指标
主要结局
Evaluate the performance of the ACP device in closure of the LAA
时间窗: 2 years post implant
Defined as absence of flow or flow of ≤3mm jet into the LAA at procedure and at 6 months, 1 year and 2 years as assessed by Transoesophageal Echocardiography (TOE).
The rate of occurrence for any reported adverse event experienced by subjects enrolled
时间窗: Through 2 years
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
AMPLATZER Cardiac Plug Clinical TrialIschemic StrokePeripheral ThromboembolismAtrial FibrillationNCT01118299Abbott Medical Devices97
已完成
不适用
AMPLATZER™ Cardiac Plug Observational Post-Approval StudyNon-valvular Atrial Fibrillation (NVAF)NCT02954237Abbott Medical Devices91
已完成
不适用
AMPLATZER Cardiac Plug (ACP) Registry-Long Term Follow-up ProtocolLeft Atrial AppendageAtrial FibrillationStrokeNCT01786486Abbott Medical Devices204
终止
不适用
C-Pulse® System: A Heart Assist Device Clinical StudyHeart FailureNCT01740596Nuwellis, Inc.38
已完成
4 期
Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary PlaquePlaque, AtheroscleroticCoronary Artery DiseaseNCT02316886Seung-Jung Park1,608